Insiders who reported open-market trades in the last 12 months at the companies Greg Keenan files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Kevin Tang - $25.14M in AUPH purchases and sales in the last 12 months
Greg Keenan is a corporate insider, tracked as SVP, Chief Medical Officer of Aurinia Pharmaceuticals Inc. (AUPH). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Greg Keenan last file a Form 4?
The most recent primary Form 4 on record is dated 10 March 2026, one of 4 filings going back to 2025.
Has Greg Keenan been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($210K) across all tracked filings.
Greg Keenan is SVP, Chief Medical Officer of Aurinia Pharmaceuticals Inc. (AUPH). 4 SEC Form 4 filings on record going back to 2025, most recently on 10 March 2026. Most recent open-market trade: sold $210K of AUPH on 1 August 2025. Lifetime open-market sales: $210K.
Recent transactions
4
The latest 4 SEC Form 4 transactions reported by Greg Keenan.
InsiderAlpha's records for Greg Keenan go back to 2025: 4 primary Form 4 filings, an average of 2.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
